Abstract:Topoisomerase II is a key target for several anti-cancer drugs used for breast cancer therapy, including doxorubicin, epirubicin and mitoxantrone. Two isoforms of topoisomerase II (alpha and beta) have been described in human cells which differ in their subcellular localisation, biochemical properties and susceptibility to inhibition by anti-cancer drugs. The relative level of expression of the alpha and beta isoforms may contribute to the degree of tumour responsiveness to different chemotherapeutic agents. To assess the relationship between expression of topoisomerase II isoforms and established prognostic factors and pathological variables, 56 primary breast tumour samples were studied. The expression of the two topoisomerase II genes was apparently not co-ordinately regulated in these tissue samples. There was no relationship between any of the commonly used pathological variables [tumour size, lymph node status, S-phase fraction (SPF)] and the level of expression of topoisomerase II beta mRNA. However, high topoisomerase II alpha gene expression was significantly associated with a high SPF (sign-rank test; P = 0.01). Moreover, the ratio of mRNA levels for topoisomerase II alpha and beta showed a stronger relationship to SPF (median raito 0.62 for tumours with SPF < 10, and 1.64 for SPF > 10; P = 0.0021, sign-rank test). As expected from previous studies, an SPF > 10 was associated with poor overall survival (P = 0.01). Immunohistochemical analysis revealed that topoisomerase II beta was widely distributed ( > 90% positive tumour cells), but that topoisomerase II alpha expression was less widely expressed, with a pattern of expression similar to that of the proliferation-dependent antigen recognised by Ki67. Because topoisomerase II gene expression showed a log-normal distribution, log-transformed data were used in multivariate analysis of relapse-free survival. This showed that lymph node status and topoisomerase II beta mRNA expression were the only significant survival factors (P = 0.001 and 0.05, respectively, with relative risks of 1.3 and 1.8). These results indicate that topoisomerase II alpha, but not beta, expression is dependent upon cellular proliferation status, but that the more widely expressed topoisomerase II beta protein may play a significant role as a target for anti-tumour therapy.

Differential expression of the topoisomerase II alpha and beta genes in human breast cancers.

Differential Expression of the Topoisomerase IIα and Β Genes in Human Breast Cancers

The Distribution and Expression of the Two Isoforms of DNA Topoisomerase II in Normal and Neoplastic Human Tissues.

Relationship Between Expression of Topoisomerase II Isoforms and Intrinsic Sensitivity to Topoisomerase II Inhibitors in Breast Cancer Cell Lines

RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference Between Mrna and Protein Expression in Predicting Prognosis of Breast Cancer Patients

The Role Of Topoisomerase Ii Alpha In Predicting Sensitivity To Anthracyclines In Breast Cancer Patients: A Meta-Analysis Of Published Literatures

Expression and Significance of Topoisomerase Ⅱα in Colorectal Caner

Expressions and Significances of Topoisomeraseⅱ and Multidrug Resistance-Associated Protein in Human Esophageal Squamous Cell Carcinoma

The Prognostic Significance of Topoisomerase II Alpha Protein in Early Stage Luminal Breast Cancer

P5-13-13: the Role of Topoisomerase IIa in Predicting Sensitivity to Anthracyclines in Breast Cancer Patients: A Meta-Analysis of Published Literatures.

The Role of Topoisomerase IIα in Predicting Sensitivity to Anthracyclines in Breast Cancer Patients: a Meta-Analysis of Published Literatures

Impact of topoisomerase IIα overexpression in the primary colon tumor on the prognosis of metastatic colorectal cancer

Human Cells Express Two Differentially Spliced Forms of Topoisomerase IIβ Mrna

Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer.

Relationship Between Expression of Topoisomerase II Isoforms and Chemosensitivity in Choroidal Melanoma.

Correlation between the Expression of Topo IIα and Ki67 in Breast Cancer and its clinical Pathological characteristics

Cyclic AMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors.

Altered Drug Interaction and Regulation of Topoisomerase IIbeta: Potential Mechanisms Governing Sensitivity of HL-60 Cells to Amsacrine and Etoposide.

Elucidating the prognostic and therapeutic significance of TOP2A in various malignancies

Correlation Between Expression of TOP2A and HER2 Signaling Pathway in Breast Cancer

The predictive and prognostic significance of pre- and post-treatment topoisomerase IIα in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer.